Yes, Cosentyx (secukinumab) can be used for the treatment of psoriatic arthritis. Cosentyx is a biologic drug that inhibits interleukin-17A (IL-17A), which is a protein that plays a key role in the development of psoriasis and psoriatic arthritis [2]. It has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis, as well as moderate to severe plaque psoriasis and ankylosing spondylitis [1].

A study published in the Journal of Clinical Medicine has shown that Cosentyx is effective in treating psoriatic arthritis. The study found that Cosentyx improved the signs and symptoms of psoriatic arthritis, including joint pain, swelling, and skin psoriasis, and also improved physical function and quality of life in patients [3].

It is important to note that Cosentyx is a prescription drug and should only be used under the guidance of a healthcare professional. Patients should discuss the risks and benefits of Cosentyx with their doctor, as well as any other medications they are taking, before starting treatment [2].

Sources:
[1] Drug Patent Watch. (n.d.). Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] Cosentyx. (n.d.). Frequently Asked Questions: Psoriatic Arthritis. Retrieved from https://www.cosentyx.com/psoriatic-arthritis/faq
[3] Mease, P. J., Kavanaugh, A., Reimold, A. M., Tahir, H., Rech, J., Hall, S., ... & van der Heijde, D. (2021). Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from a Phase 3 Trial. Journal of Clinical Medicine, 10(7), 1453. https://doi.org/10.3390/jcm10071453